Hussman Strategic Advisors Inc. Increases Holdings in Astrana Health, Inc. $ASTH

Key Points

• Hussman Strategic Advisors increased its stake in Astrana Health by 200% in Q4, buying an additional 42,000 shares to hold 63,000 shares valued at about $1.56 million (0.11% of the company).
• Astrana beat estimates for the quarter, reporting $0.54 EPS versus a $0.15 consensus and revenue of $950.5 million, up 42.9% year‑over‑year.
• The stock trades near its 52‑week high (opened $34.89 vs a $35.38 high), has a market cap of ~$1.94 billion and a PE of 75.85, with a consensus analyst rating of “Moderate Buy” and a $34.86 target.

Hussman Strategic Advisors Inc. grew its holdings in shares of Astrana Health, Inc. (NASDAQ:ASTH - Free Report) by 200.0% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 63,000 shares of the company's stock after buying an additional 42,000 shares during the period. Hussman Strategic Advisors Inc. owned 0.11% of Astrana Health worth $1,563,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of ASTH. Royal Bank of Canada lifted its holdings in Astrana Health by 6.5% during the 1st quarter. Royal Bank of Canada now owns 278,619 shares of the company's stock worth $8,640,000 after buying an additional 17,028 shares during the last quarter. AQR Capital Management LLC purchased a new stake in Astrana Health during the 1st quarter worth about $933,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Astrana Health by 5.2% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 25,768 shares of the company's stock worth $799,000 after purchasing an additional 1,263 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of Astrana Health by 4,365.2% during the first quarter. Jones Financial Companies Lllp now owns 11,163 shares of the company's stock worth $346,000 after purchasing an additional 10,913 shares in the last quarter. Finally, Intech Investment Management LLC increased its position in shares of Astrana Health by 5.8% during the first quarter. Intech Investment Management LLC now owns 44,586 shares of the company's stock worth $1,383,000 after purchasing an additional 2,462 shares in the last quarter. 52.77% of the stock is owned by hedge funds and other institutional investors.

Astrana Health Stock Performance

Shares of ASTH stock opened at $34.89 on Friday. The stock's 50-day moving average price is $26.43 and its 200 day moving average price is $25.61. The company has a quick ratio of 1.40, a current ratio of 1.40 and a debt-to-equity ratio of 1.25. The stock has a market capitalization of $1.94 billion, a PE ratio of 75.85 and a beta of 0.98. Astrana Health, Inc. has a 52-week low of $18.08 and a 52-week high of $35.38.

Astrana Health (NASDAQ:ASTH - Get Free Report) last posted its quarterly earnings data on Monday, March 2nd. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.15 by $0.39. The firm had revenue of $950.53 million during the quarter, compared to the consensus estimate of $930.46 million. Astrana Health had a return on equity of 5.59% and a net margin of 0.71%.The firm's revenue was up 42.9% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.15) EPS. As a group, equities research analysts forecast that Astrana Health, Inc. will post 1.44 EPS for the current year.

Analyst Ratings Changes

A number of research firms have recently commented on ASTH. Zacks Research upgraded Astrana Health from a "strong sell" rating to a "hold" rating in a research report on Wednesday, March 11th. Robert W. Baird lifted their target price on Astrana Health from $37.00 to $40.00 and gave the stock an "outperform" rating in a research report on Wednesday, April 15th. BTIG Research cut their target price on Astrana Health from $45.00 to $40.00 and set a "buy" rating on the stock in a research report on Monday, February 2nd. Truist Financial lifted their target price on Astrana Health from $37.00 to $38.00 and gave the stock a "buy" rating in a research report on Friday, March 13th. Finally, Weiss Ratings upgraded Astrana Health from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Wednesday. Six analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $34.86.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.